Immutep Reports Significant Annual Loss While Maintaining Strong Cash Position

Clinical-stage biotechnology company Immutep disclosed a substantial net loss of A$61.4 million for its most recent fiscal year in an announcement that preceded its full financial results release. The news, which emerged ahead of schedule, sent the company’s NASDAQ-listed shares to $1.66 in after-hours trading.

Despite reporting considerable financial losses driven by aggressive research investment, Immutep maintains a robust cash position of A$129.69 million. This financial cushion is projected to fund operations through late 2026, providing substantial runway for the company’s ambitious clinical development programs.

Accelerated Research Spending and Clinical Advancements

The company’s research and development expenditures surged to A$16.2 million during the second quarter alone, marking a significant increase from the A$9.5 million spent in the preceding quarter. This accelerated cash burn reflects Immutep’s intensified focus on advancing its pipeline of LAG-3 immunotherapies.

Central to the company’s development strategy is the pivotal TACTI-004 Phase III trial, which is currently enrolling patients across 78 sites in 23 countries. This global study is evaluating the combination of eftilagimod alpha and KEYTRUDA® as a potential treatment for lung cancer.

The company received encouraging regulatory feedback in early August when the FDA provided positive commentary on the late-stage development of eftilagimod alpha for head and neck cancers. Additionally, Immutep’s Phase II EFTISARC-NEO study for soft tissue sarcoma successfully achieved its primary endpoint.

Should investors sell immediately? Or is it worth buying Immutep?

Early data for IMP761, an innovative therapy targeting autoimmune diseases, has demonstrated significant T-cell suppression with favorable tolerability. Further results from this program are anticipated in the second half of 2025.

Mixed Market Signals and Technical Outlook

While one research analyst maintains a $7.00 price target with a buy recommendation, technical indicators present a more cautious short to medium-term perspective for Immutep’s stock.

• Current trading price: $1.66
• Support level: approximately $1.64
• Resistance level: near $1.70
• Previous session performance: declined 1.19%

The substantial bid-ask spread between $1.51 and $1.91 suggests limited market liquidity, presenting additional considerations for potential investors.

Market attention now turns to the company’s forthcoming annual report and any updated guidance that may provide further insight into Immutep’s development timeline and financial trajectory. The critical question remains whether the company’s clinical programs can deliver on their promise and reverse the current negative momentum in its share price.